Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Cediranib

Catalog No: tcsc0119

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Specifications

CAS No:
288383-20-0

Formula:
$C_{25}H_{27}FN_4O_3$

Pathway:
Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Autophagy

Target:
VEGFR;PDGFR;Autophagy

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 49 mg/mL (108.77 mM)

Alternative Names:
AZD2171

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
450.51

Product Description

Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available **VEGFR** tyrosine kinase inhibitor with **IC_{50}**s of
IC50 & Target: IC50: [1]

In Vitro: In human umbilical vein endothelial cells, Cediranib inhibits VEGF-stimulated proliferation and KDR phosphorylation with IC_{50} values of 0.4 and 0.5 nM, respectively. In a fibroblast/endothelial cell coculture model of vessel sprouting, Cediranib also reduces vessel area, length, and branching at subnanomolar concentrations[1].

In Vivo: Once-daily oral administration of Cediranib ablates experimental (VEGF-induced) angiogenesis and inhibits endochondral ossification in bone or corpora luteal development in ovary; physiologic processes that are highly dependent upon neovascularization. The growth of established human tumor xenografts (colon, lung, prostate, breast, and ovary) in athymic mice is inhibited dose-dependently by Cediranib, with chronic administration of 1.5 mg per kg per day producing statistically significant inhibition in all models. A histologic analysis of Calu-6 lung tumors treated with Cediranib reveals a reduction in microvessel density within 52 hours that becomes progressively greater with the duration of treatment. These changes are indicative of vascular regression within tumors[1].